Alterity Therapeutics (ATHE) has released an update.
Alterity Therapeutics has presented promising data at the AAN 2024 Annual Meeting, showcasing the potential of their drug, ATH434, in improving motor functions and targeting biomarkers in Parkinson’s disease and Multiple System Atrophy (MSA). Results from a primate study and Phase 2 clinical trials indicate ATH434’s ability to reduce abnormal brain iron and inhibit α-synuclein aggregation, offering hope for treating these neurodegenerative diseases. The company’s presentations highlighted significant correlations between biomarkers and disease severity, supporting ATH434’s continued development.
For further insights into ATHE stock, check out TipRanks’ Stock Analysis page.
